{"id":49546,"date":"2015-03-31T00:00:00","date_gmt":"2015-03-30T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/"},"modified":"2020-11-18T14:55:41","modified_gmt":"2020-11-18T13:55:41","slug":"avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/","title":{"rendered":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome"},"content":{"rendered":"<p>The patent to be issued from this allowed application covering an invention from Spanish leading neuroscience center<a href=\"http:\/\/in.umh.es\/origenes.aspx\" target=\"_blank\" rel=\"noopener noreferrer\"> Instituto de Neurociencias de Alicante\u00a0(IN)<\/a><a href=\"http:\/\/in.umh.es\/origenes.aspx\">\u00a0<\/a>and exclusively licensed to Avizorex carries a patent term to at least 2031, and represents a significant addition in Avizorex current patent portfolio. The company will continue prosecuting the patent application in other jurisdictions.\u00a0<\/p>\n<p>\u201cThis is a very significant milestone that strengthens our IP position and paves the way to aggresively continue building a solid IP portfolio around our inventions and products in the area of Dry Eye Syndrome\u201d, said Patrick Tresserras, Avizorex\u00a0Founder and CEO. \u201cWe are looking forward to expanding our patent portfolio as we further investigate the safety and efficacy profile of AVX-012\u201d.\u00a0<\/p>\n<p>Avizorex Pharma,\u00a0a spin-off of Miguel Hern\u00e1ndez University, was founded in 2013 on the grounds of neurobiological research performed by the Group on Ocular Sensory Innervation led by Prof. Carlos Belmonte at the <a href=\"http:\/\/in.umh.es\/origenes.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">Instituto de Neurociencias de Alicante\u00a0(IN)<\/a>\u00a0and studies novel pharmacological approaches to treat chronic dry eye.\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/noticies\/-\/noticia\/not_inveready-entra-en-el-capital-de-la-biotecnologica-avizorex?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Davizorex%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Davizorex%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">Related news [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_006370&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3Davizorex%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Avizorex Pharma<\/a>, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has\u00a0announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (<a href=\"http:\/\/www.uspto.gov\/\">USPTO<\/a>) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye Syndrome (DES) with a new mechanism of action currently undergoing late-stage preclinical studies.\u00a0Avizorex Pharma is an ophthalmology biotech backed by I<a href=\"http:\/\/www.inveready.com\/en\" target=\"_blank\" rel=\"noopener noreferrer\">nveready Venture Capital<\/a> with headquarters in Elche (Alicante, Spain) and offices at Barcelona Science Park (PCB).<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":53301,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49546","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Avizorex Pharma, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has\u00a0announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye Syndrome (DES) with a new mechanism of action currently undergoing late-stage preclinical studies.\u00a0Avizorex Pharma is an ophthalmology biotech backed by Inveready Venture Capital with headquarters in Elche (Alicante, Spain) and offices at Barcelona Science Park (PCB). \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-30T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:55:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1206\" \/>\n\t<meta property=\"og:image:height\" content=\"777\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome\",\"datePublished\":\"2015-03-30T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/\"},\"wordCount\":184,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/16057067345fb523ee89e52.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/\",\"name\":\"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/16057067345fb523ee89e52.jpeg\",\"datePublished\":\"2015-03-30T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/16057067345fb523ee89e52.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/16057067345fb523ee89e52.jpeg\",\"width\":1206,\"height\":777},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona","og_description":"Avizorex Pharma, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has\u00a0announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye Syndrome (DES) with a new mechanism of action currently undergoing late-stage preclinical studies.\u00a0Avizorex Pharma is an ophthalmology biotech backed by Inveready Venture Capital with headquarters in Elche (Alicante, Spain) and offices at Barcelona Science Park (PCB). \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2015-03-30T23:00:00+00:00","article_modified_time":"2020-11-18T13:55:41+00:00","og_image":[{"width":1206,"height":777,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome","datePublished":"2015-03-30T23:00:00+00:00","dateModified":"2020-11-18T13:55:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/"},"wordCount":184,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/","url":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/","name":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg","datePublished":"2015-03-30T23:00:00+00:00","dateModified":"2020-11-18T13:55:41+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2015\/03\/16057067345fb523ee89e52.jpeg","width":1206,"height":777},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-announces-grant-of-u-s-patent-for-its-treatment-of-dry-eye-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49546"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49546\/revisions"}],"predecessor-version":[{"id":53300,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49546\/revisions\/53300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/53301"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}